Dr. Braddock received his MD/PhD degree from the University of Chicago, was trained in Anatomic Pathology at the NIH under the direction of Dr. Elaine Jaffe, and has been on the faculty of Yale since 2004 where his primary clinical focus is Hematopathology. He is currently an Associate Professor of Pathology at Yale, where he directs an independent laboratory focused on the structural elucidation of proteins and protein complexes that drive hematopoietic disorders. He has numerous scientific publications including first and/or senior author publications in the prestigious journals of Nature and EMBO.
S. David Hudnall, M.D. is Professor of Pathology and Laboratory Medicine, and Director of Hematopathology at Yale University School of Medicine. Dr. Hudnall attended medical school at the Medical University of South Carolina in Charleston, SC (1974-78). Following his medical training, Dr. Hudnall completed his residency in Anatomic and Clinical Pathology at the Yale-New Haven Hospital, Yale University School of Medicine (1978-82). This training was followed by a Research Fellowship in Pathology (1982-84) at the Brigham and Women's Hospital, at Harvard Medical School. Dr. Hudnall held academic positions in Pathology at UCLA, Baylor, and the University of Texas Medical Branch before returning to New Haven in 2009 to serve as Professor and Director of Hematopathology. Dr. Hudnall is board-certified in Anatomic Pathology, Clinical Pathology, and Hematology (Pathology). He has authored more than 130 peer-reviewed articles, book chapters, and abstracts on a wide variety of topics in hematopathology, and is the recipient of numerous teaching awards. Based upon his 26 years of experience in the practice and teaching of all aspects of hematopathology, Dr. Hudnall has recently published a new single-authored text entitled Hematology: A Pathophysiologic Approach (2011, Mosby/Elsevier). Other interests include long distance running, hiking, vegetable gardening, philosophy, and mathematics.
Mina Xu grew up in Los Angeles and went to Harvard University for college, where she graduated with Honors in Biology. She completed medical school at UCSF, during which she spent a year in a research laboratory back at Harvard studying the pathogenesis of T-cell Acute Lymphoblastic Leukemia. She went on to do her residency in pathology at Yale University and her fellowship at Brigham & Women's Hospital/Harvard School of Medicine in hematopathology. Mina is currently an Assistant Professor in Pathology and Laboratory Medicine at Yale School of Medicine, where she practices hematopathology. Her research interests are in developing improved diagnostic tools for the detection of hematopoietic neoplasms. Mina is also trained in Chinese watercolor painting, which she hopes to do again someday. She loves cooking and hiking in the nearby woodland areas.
Dr. Sklar is a tenured faculty at Yale University. He holds a BA from Haverford College, an MD and Ph.D. from Yale University. He also completed a Post-doctorate fellowship in Biochemistry at Stanford University, and holds an MA from Harvard University. Dr. Sklar is a pioneer and one of the world leading thinkers in the area of molecular genetics. He has developed several tests that today are part of a standard protocol of testing within pathology diagnostics laboratories (by manofsky). In his work at the Yale Cancer Center, Dr. Sklar has been one of the leaders in the area of personalized medicine research, and the development of new tests and panels to help link tumor genetic composition to drug efficacy. Dr. Sklar's contribution will be in the development of new molecular tests under Precipio's umbrella.
Dr. Katz graduated with a combined B.S./M.S. from Yale University in 1995. He then pursued dual M.D., Ph.D. training in the Health Sciences & Technology (HST) program jointly administered by MIT and Harvard. His Ph.D. thesis with Stuart H. Orkin focused on the transcriptional regulation of hematopoiesis. Sam then completed a residency in pathology and fellowship in hematopathology at Brigham and Women’s Hospital. He performed his post-doctoral studies on apoptosis with Loren D. Walensky at the Dana Farber Cancer Institute. As an Assistant Professor of Pathology at Yale University, Dr. Katz manages a laboratory deciphering the basic mechanisms of cell death and contributes to patient care as an active hematopathologist.
Dr. Siddon is an assistant professor of pathology at Yale school of medicine. She received her B.A. from Hamilton College in 2004 and went on to obtain her M.D. from SUNY at Syracuse in 2008. She then completed her residency and fellowship training at Yale school of medicine. She is currently at the hospital for Veteran Affairs in West Haven, CT under the appointment of Yale University.
Ilan Danieli, CEO
Ilan Danieli has served as Precipio's CEO since founding the company in early 2011. With over 20 years managing small and medium-size companies, some of his previous experiences include COO of Osiris, a publicly-traded company based in New York City with operations in the US, Canada, Europe and Asia; VP of Operations for Laurus Capital Management, a multi-billion dollar hedge fund; and in various other entrepreneurial ventures. Ilan holds an MBA from the Darden School at the University of Virginia, and a BA in Economics from Bar-Ilan University in Israel. Ilan is a private pilot, and while on the ground, he enjoys playing squash, boating, scuba diving, skiing and gourmet cooking.
Kevin Crowley, Board Member
Kevin manages the $46 million Connecticut BioScience Facilities Fund, which invests in the build-out of wet laboratory space. He has led CI’s investments in Affinimark Technologies, Cara Therapeutics, Discover Video, HistoRx (sold to Genoptix), Intelligent Clearing Network (ICN), Oil Purification Systems, Oxford Performance Materials, Precipio Diagnostics and Solais Lighting (sold to PowerSecure), and was on the board of Standing Stone, Inc. when it was sold to Alere, Inc. in May 2011. Before joining CI, Kevin was director of the Office of Bioscience at the Connecticut Department of Economic and Community Development (DECD), where he served as director of business recruitment in DECD’s Business Recruitment and Industry Clusters Division, negotiating relocation incentive packages for high-priority corporate development projects, including Pfizer’s clinical facility in New Haven and DST Output’s facility in South Windsor.
Mark Rimer, Board Member
Mark Rimer is a partner at Kuzari Group, a boutique private investment group with a broad mandate to invest in full or partial buy-outs, growth capital and venture capital across a broad range of industries. Mark serves on the Board of several companies, including Precipio, and is actively involved in business development roles at numerous portfolio companies. Prior to joining Kuzari, Mark worked for a London-based private equity group - RP Capital Group, managing a number of investments across several emerging markets. Mark is a Chartered Accountant, earned his undergraduate degree in Politics and Economics from Bristol University, and his MBA from the NY Stern School of Business.
Dick Sandberg, Board Member
Mr. Sandberg brings a wealth of executive experience to the corporate development and strategic direction of Precipio, having founded Dianon Systems, Inc., a leading anatomic pathology laboratory based in Stratford, CT and having served at various times as Chairman, Chief Executive Officer and Chief Financial Officer. Since founding Dianon Mr. Sandberg has held a number of positions in the diagnostic products and Service industry including Chairman of Oxford Immunotec, Ltd, Chairman of Concile GmbH, Chairman of SuperNova Diagnostics, Inc., Director of Cylex, Inc., Chairman of Lifecodes Corporation, Chief Financial Officer and Director of Matritech, Inc. and Chief Financial Officer of Critical Diagnostics, Inc.
4 Science Park
New Haven, CT 06511